Literature DB >> 15143475

The hamster as an animal model for eastern equine encephalitis--and its use in studies of virus entrance into the brain.

Slobodan Paessler1, Patricia Aguilar, Michael Anishchenko, Hui-Qun Wang, Judith Aronson, Gerald Campbell, Ann-Sophie Cararra, Scott C Weaver.   

Abstract

Eastern equine encephalitis virus (EEEV) produces the most severe human arboviral diseases in the United States, with mortality rates of 30%-70%. Vasculitis associated with microhemorrhages in the brain dominates the pathological picture in fatal human eastern equine encephalitis, and neuronal cell death is detectable during the late stage of the disease. We describe use of the golden hamster to study EEEV-induced acute vasculitis and encephalitis. In hamsters, EEEV replicates in visceral organs, produces viremia, and penetrates the brain. The pathological manifestations and antigen distribution in the brain of a hamster are similar to those described in human cases of EEEV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143475     DOI: 10.1086/383246

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.

Authors:  Michael Zasloff; A Paige Adams; Bernard Beckerman; Ann Campbell; Ziying Han; Erik Luijten; Isaura Meza; Justin Julander; Abhijit Mishra; Wei Qu; John M Taylor; Scott C Weaver; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

Review 3.  An Overview of Animal Models for Arthropod-Borne Viruses.

Authors:  Erin S Reynolds; Charles E Hart; Meghan E Hermance; Douglas L Brining; Saravanan Thangamani
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

Review 4.  Alphaviruses: population genetics and determinants of emergence.

Authors:  Scott C Weaver; Richard Winegar; Ian D Manger; Naomi L Forrester
Journal:  Antiviral Res       Date:  2012-04-19       Impact factor: 5.970

5.  Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in Mammalian cells.

Authors:  Olga Petrakova; Eugenia Volkova; Rodion Gorchakov; Slobodan Paessler; Richard M Kinney; Ilya Frolov
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Susceptibility of the Aotus nancymaae owl monkey to eastern equine encephalitis.

Authors:  Benjamin J Espinosa; Scott C Weaver; Slobodan Paessler; Douglas Brining; Milagros Salazar; Tadeusz Kochel
Journal:  Vaccine       Date:  2009-01-30       Impact factor: 3.641

7.  Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of New World cutaneous leishmaniasis.

Authors:  Claudia M Espitia; Weiguo Zhao; Omar Saldarriaga; Yaneth Osorio; Lisa M Harrison; Michael Cappello; Bruno L Travi; Peter C Melby
Journal:  BMC Immunol       Date:  2010-06-22       Impact factor: 3.615

8.  Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis.

Authors:  Christina L Gardner; Crystal W Burke; Mulu Z Tesfay; Pamela J Glass; William B Klimstra; Kate D Ryman
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

9.  Common marmosets (Callithrix jacchus) as a nonhuman primate model to assess the virulence of eastern equine encephalitis virus strains.

Authors:  A Paige Adams; Judith F Aronson; Suzette D Tardif; Jean L Patterson; Kathleen M Brasky; Robert Geiger; Melissa de la Garza; Ricardo Carrion; Scott C Weaver
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

10.  Pathogenesis of aerosolized Eastern Equine Encephalitis virus infection in guinea pigs.

Authors:  Chad J Roy; Douglas S Reed; Catherine L Wilhelmsen; Justin Hartings; Sarah Norris; Keith E Steele
Journal:  Virol J       Date:  2009-10-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.